Uçucu Süheyl, Karabıyık Talha, Azik Fatih
Ministry of Public Health Care Laboratory, Department of Medical Biochemistry, Muğla, Turkey.
Bursa City Hospital, Department of Medical Biochemistry, Bursa, Turkey.
J Med Biochem. 2022 Feb 2;41(1):32-39. doi: 10.5937/jomb0-30420.
HbS/b cases having clinical, hematologic and electrophoretic similarities cannot be sufficiently distinguished from sickle cell anemia cases and are misdiagnosed as sickle cell anemia. This study will investigate the congruence between the HPLC thalassemia scanning tests and the laboratory findings compared to the DNA sequence analysis results of the patients diagnosed with SCA between 2016 and 2020. This study also aims to indicate the current status to accurately diagnose sickle cell anemia and HbS/b in the light of hematologic, electrophoretic and molecular studies.
Fourteen patients who were diagnosed with SCA in hospitals at different cities in Turkey and followed by the Thalassemia Diagnosis, Treatment and Research Center, Muğla Sıtkı Koçman University were included in this retrospective study. The socio-demographic characteristics, hemogram, hemoglobin variant analysis results and DNA chain analysis results of the patients were taken from the database of the centre and then examined. The informed consents were taken from the patients. The patients were administered a survey containing questions about transfusion history and diagnostic awareness. The Beta-Thalassemia mutations were analysed using a DNA sequencer (Dade Behring, Germany) based on the Sanger method.
According to the DNA sequence analysis, the results of these patients diagnosed with SCA in hospitals in different cities of Turkey were the following: of 14 patients, 8 had HbS/b0, and HbS/b+ and one had HbS carrier, and one had Hb-O, and three had SCA. The patient with HbS carrier status also contains three additional mutations, all of which are heterozygous. We discovered that although two of three mutations, which are c.315+16G>C and c.316-185C>T, are previously reported as benign, at least one of the two mentioned mutations, when combined with HbS, causes transfusion-dependent HbS/b.
Briefly, HbSS and HbS/b thalassemia genotypes cannot be definitely characterized by electrophoretic and hematologic data, resulting in misdiagnosis. c.315+16G>C and c.316-185C>T are previously reported as benign; at least one of the two mentioned mutations, when combined with HbS, causes transfusion-dependent HbS/b. In undeveloped or some developing countries, molecular diagnosis methods and genetic analyses cannot be used. If mutation analyses could be performed, then such differential diagnosis errors would reduce. However, if mutation analysis cannot be performed, other methods such as HPLC, capillary electrophoresis absolutely be sought to have insight into the parental carriage status.
具有临床、血液学和电泳相似性的HbS/b病例无法与镰状细胞贫血病例充分区分,常被误诊为镰状细胞贫血。本研究将调查2016年至2020年间被诊断为镰状细胞贫血(SCA)患者的高效液相色谱(HPLC)地中海贫血扫描试验结果与实验室检查结果之间的一致性,并与DNA序列分析结果进行比较。本研究还旨在根据血液学、电泳和分子研究结果,阐明准确诊断镰状细胞贫血和HbS/b的现状。
本回顾性研究纳入了14例在土耳其不同城市医院被诊断为SCA并由穆拉·锡特基·科克曼大学地中海贫血诊断、治疗和研究中心随访的患者。患者的社会人口学特征、血常规、血红蛋白变异分析结果和DNA链分析结果均取自该中心数据库并进行检查。获得了患者的知情同意书。对患者进行了一项包含输血史和诊断认知问题的调查。采用基于桑格法的DNA测序仪(德国达德拜林公司)分析β地中海贫血突变。
根据DNA序列分析,这些在土耳其不同城市医院被诊断为SCA的患者结果如下:14例患者中,8例为HbS/b0、HbS/b+,1例为HbS携带者,1例为Hb-O,3例为SCA。HbS携带者状态的患者还存在另外三种突变,均为杂合子。我们发现,虽然c.315+16G>C和c.316-185C>T这三种突变中的两种先前被报告为良性,但上述两种突变中至少有一种与HbS结合时,会导致依赖输血的HbS/b。
简而言之,HbSS和HbS/b地中海贫血基因型无法通过电泳和血液学数据明确表征,从而导致误诊。c.315+16G>C和c.316-185C>T先前被报告为良性;上述两种突变中至少有一种与HbS结合时,会导致依赖输血的HbS/b。在不发达国家或一些发展中国家,无法使用分子诊断方法和基因分析。如果能够进行突变分析,那么此类鉴别诊断错误将会减少。然而,如果无法进行突变分析,则绝对需要寻求其他方法,如HPLC、毛细管电泳,以了解父母的携带状态。